Related Experiment Videos
Antiestrogen therapy: uncertainties and risk assessment
Oncology (Williston Park, N.Y.)
|April 29, 1998
Summary
Tamoxifen, a breast cancer drug, is linked to increased uterine tumors. Research suggests tamoxifen
Area of Science:
- Oncology
- Pharmacology
- Toxicology
Background:
- Tamoxifen is a widely used antiestrogenic drug for breast cancer adjuvant therapy.
- Clinical trials show a 3-6 fold increase in uterine tumors associated with tamoxifen use.
- Tamoxifen is a mutagenic, genotoxic hepatocarcinogen in rats, independent of its antiestrogen activity.
Purpose of the Study:
- To investigate the mechanism behind tamoxifen-associated endometrial cancer.
- To evaluate two hypotheses: genotoxic DNA damage versus estrogenic promotion of tumors.
Main Methods:
- Review of clinical trial data and existing research on tamoxifen's effects.
- Analysis of proposed mechanisms for endometrial cancer development.
Main Results:
- Evidence for tamoxifen's genotoxic effect in the uterus is contentious.
- The estrogenic effects of tamoxifen are considered more likely to promote endometrial tumor development.
Conclusions:
- Tamoxifen's estrogenic activity, not genotoxicity, is the probable cause of endometrial tumors.
- Further research may clarify the precise molecular mechanisms involved.